Novozymes recently presented a new business strategy meant to advance the company's future by, among other things, doubling sales. The underlying idea is to create a "biotechnology powerhouse" by exploring a wide range of new business areas between 2025 and 2030 and thus achieve the full potential of biotech diversification.
Here, Novozymes Executive Vice President Amy Byrick revealed that, rather than betting its chips on only a few items, the group will develop up to 15 new ventures annually.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for EnergyWatch has now started
With your free trial you get:
Full access to all locked articles on EnergyWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.